MedTrace Logo

Dienogest in Perimenopausal Women With Adenomyosis

NCT05751876 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 87

Last updated 2023-03-02

No results posted yet for this study

Summary

Between September 2018 and December 2021, women who did not want further childbearing and received dienogest treatment for dysmenorrhea and/or hypermenorrhea were included in a retrospective chart review. Dienogest 2mg was prescribed once per day orally after completing the above-mentioned exam. The patient would return to our clinic on the 1st, 3rd, and 6th then every 3 months for a prescription. The primary outcome was successfully long-term (more than a year) dienogest use for pain and/or bleeding control. The secondary outcomes were the reasons for discontinuing dienogest treatment and the predictor of successful long-term treatment.

Conditions

  • Adenomyosis
  • Medication Adherence

Interventions

DRUG

Dienogest

Dienogest 2mg was prescribed once per day orally

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Chi-Hau Chen, MD, PhD · National Taiwan University Hospital

Eligibility

Min Age
40 Years
Max Age
53 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05751876 on ClinicalTrials.gov